Clonal hematopoiesis and atherosclerosis

New England Journal of Medicine

Volumn 377, Issue 14, 2017, Pages 1400-1401

  Cassinat, Bruno ^a   Harrison, Claire ^b   Kiladjian, Jean Jacques ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ATHEROSCLEROSIS; CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL; GENE MUTATION; HEMATOCRIT; HEMATOPOIESIS; HUMAN; JAK2 GENE; LETTER; LEUKOCYTE COUNT; MOLECULAR GENETICS; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTHEMIA; CELL CLONE;

ATHEROSCLEROSIS; CLONE CELLS; HEMATOPOIESIS;

EID: 85030484595     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1710381     Document Type: Letter

References (5)

1. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 2017;377:111-21.
2. Spivak JL. Myeloproliferative neoplasms. N Engl J Med 2017; 376:2168-81.
3. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391-405.
4. Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol 2015;1:97-105.
5. Kiladjian JJ, Giraudier S, Cassinat B. Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia 2016;30:776-81.